Status:
ENROLLING_BY_INVITATION
Continuous Renal Replacement Therapy Intensity in Hyperammonemia
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Collaborating Sponsors:
FIPE - Fundo de Incentivo a Pesquisa do Hospital de Clínicas de Porto Alegre
Conditions:
Acute Liver Failure
Acute on Chronic Liver Failure (ACLF)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) are life-threatening conditions often associated with hyperammonemia, hepatic encephalopathy, and multi-organ dysfunction. Ammonia p...
Detailed Description
Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) are critical conditions characterized by rapid deterioration in hepatic function, coagulopathy, hepatic encephalopathy, and multi-or...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Diagnosis of acute liver failure (ALF) or acute-on-chronic liver failure (ACLF) Presence of hyperammonemia, defined as: Arterial ammonia \>72 μmol/L and hepatic encephalopathy grade ≥2 or Arterial ammonia \>100 μmol/L regardless of encephalopathy grade
- Indication for continuous renal replacement therapy (CRRT), as determined by the attending medical team
- Informed consent provided by the patient or legal representative
Exclusion
- Age \< 18 years
- Pregnancy
- Diagnosis of acute liver failure (ALF) in the context of severe hemodynamic instability
- ALF secondary to ischemic hepatic injury
Key Trial Info
Start Date :
March 14 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 14 2029
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT06987604
Start Date
March 14 2025
End Date
May 14 2029
Last Update
June 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil, 90410-000